<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26343814</article-id><article-id pub-id-type="pmc">5057299</article-id><article-id pub-id-type="doi">10.1111/dom.12572</article-id><article-id pub-id-type="publisher-id">DOM12572</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes</article-title><alt-title alt-title-type="left-running-head">Chilton et al.</alt-title></title-group><contrib-group><contrib id="dom12572-cr-0001" contrib-type="author"><name><surname>Chilton</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12572-cr-0002" contrib-type="author"><name><surname>Tikkanen</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12572-cr-0003" contrib-type="author"><name><surname>Cannon</surname><given-names>C. P.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12572-cr-0004" contrib-type="author"><name><surname>Crowe</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12572-cr-0005" contrib-type="author"><name><surname>Woerle</surname><given-names>H. J.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12572-cr-0006" contrib-type="author"><name><surname>Broedl</surname><given-names>U. C.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12572-cr-0007" contrib-type="author" corresp="yes"><name><surname>Johansen</surname><given-names>O. E.</given-names></name><xref ref-type="aff" rid="dom12572-aff-0005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="dom12572-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Medicine</named-content><institution>University of Texas Health Science Center</institution><named-content content-type="city">San Antonio</named-content><named-content content-type="country-part">TX</named-content><country country="US">USA</country></aff><aff id="dom12572-aff-0002"><label><sup>2</sup></label><institution>Helsinki University Hospital and Minerva Institute for Medical Research, University of Helsinki</institution><named-content content-type="city">Helsinki</named-content><country country="FI">Finland</country></aff><aff id="dom12572-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Cardiology</named-content><institution>Harvard Clinical Research Institute</institution><named-content content-type="city">Boston</named-content><named-content content-type="country-part">MA</named-content><country country="US">USA</country></aff><aff id="dom12572-aff-0004"><label><sup>4</sup></label><institution>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG</institution><named-content content-type="city">Ingelheim</named-content><country country="DE">Germany</country></aff><aff id="dom12572-aff-0005"><label><sup>5</sup></label><institution>Boehringer Ingelheim Norway KS</institution><named-content content-type="city">Asker</named-content><country country="NO">Norway</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Odd Erik Johansen, Boehringer Ingelheim Norway KS, Asker, Norway.<break/>
E&#x02010;mail: <email>odd_erik.johansen@boehringer-ingelheim.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>17</volume><issue>12</issue><issue-id pub-id-type="doi">10.1111/dom.2015.17.issue-12</issue-id><fpage>1180</fpage><lpage>1193</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>01</day><month>9</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-17-1180.pdf"/><abstract id="dom12572-abs-0001"><sec id="dom12572-sec-0001"><title>Aims</title><p id="dom12572-para-0001">To determine the effects of empagliflozin on blood pressure (<styled-content style="fixed-case">BP</styled-content>) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (<styled-content style="fixed-case">T2DM</styled-content>).</p></sec><sec id="dom12572-sec-0002"><title>Methods</title><p id="dom12572-para-0002">We conducted a <styled-content style="italic-in-any-context">post hoc</styled-content> analysis of data from a phase <styled-content style="fixed-case">III</styled-content> trial in patients with <styled-content style="fixed-case">T2DM</styled-content> and hypertension receiving 12&#x02009;weeks' empagliflozin and four phase <styled-content style="fixed-case">III</styled-content> trials in patients with <styled-content style="fixed-case">T2DM</styled-content> receiving 24&#x02009;weeks' empagliflozin (cohort 1, n&#x02009;=&#x02009;823; cohort 2, n&#x02009;=&#x02009;2477). <styled-content style="fixed-case">BP</styled-content> was measured using 24&#x02010;h <styled-content style="fixed-case">BP</styled-content> monitoring (cohort 1) or seated office measurements (cohort 2).</p></sec><sec id="dom12572-sec-0003"><title>Results</title><p id="dom12572-para-0003">Empagliflozin reduced systolic <styled-content style="fixed-case">BP</styled-content> (<styled-content style="fixed-case">SBP</styled-content>) and diastolic <styled-content style="fixed-case">BP</styled-content> in both cohorts (p&#x02009;&#x0003c;&#x02009;0.001 vs placebo), without increasing heart rate. Empagliflozin reduced pulse pressure (<styled-content style="fixed-case">PP</styled-content>; adjusted mean difference vs placebo cohort 1: &#x02212;2.3 <styled-content style="fixed-case">mmHg</styled-content>; cohort 2: &#x02212;2.3 <styled-content style="fixed-case">mmHg</styled-content>), mean arterial pressure (<styled-content style="fixed-case">MAP</styled-content>; cohort 1, &#x02212;2.3 <styled-content style="fixed-case">mmHg</styled-content>; cohort 2, &#x02212;2.1 <styled-content style="fixed-case">mmHg</styled-content>) and double product (cohort 1, &#x02212;385 <styled-content style="fixed-case">mmHg</styled-content>&#x02009;&#x000d7;&#x02009;bpm; cohort 2, &#x02212;369 <styled-content style="fixed-case">mmHg</styled-content>&#x02009;&#x000d7;&#x02009;bpm) all p&#x02009;&#x0003c;&#x02009;0.001 vs placebo. There was a trend towards a reduction in the ambulatory arterial stiffness index (<styled-content style="fixed-case">AASI</styled-content>) with empagliflozin in cohort 1 (p&#x02009;=&#x02009;0.059 vs placebo). <styled-content style="fixed-case">AASI</styled-content> was not measured in cohort 2. Subgroup analyses showed that there were greater reductions in <styled-content style="fixed-case">PP</styled-content> with increasing baseline <styled-content style="fixed-case">SBP</styled-content> in cohort 1 (p&#x02009;=&#x02009;0.092). In cohort 2, greater reductions in <styled-content style="fixed-case">MAP</styled-content> were achieved in patients with higher baseline <styled-content style="fixed-case">SBP</styled-content> (p&#x02009;=&#x02009;0.027) and greater reductions in <styled-content style="fixed-case">PP</styled-content> were observed in older patients (p&#x02009;=&#x02009;0.011).</p></sec><sec id="dom12572-sec-0004"><title>Conclusions</title><p id="dom12572-para-0004">Empagliflozin reduced <styled-content style="fixed-case">BP</styled-content> and had favourable effects on markers of arterial stiffness and vascular resistance.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12572-kwd-0001">cardiovascular disease</kwd><kwd id="dom12572-kwd-0002">phase <styled-content style="fixed-case">III</styled-content> study</kwd><kwd id="dom12572-kwd-0003"><styled-content style="fixed-case">SGLT2</styled-content> inhibitor</kwd><kwd id="dom12572-kwd-0004">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Accumetrics</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Arisaph</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Astra Zeneca</funding-source></award-group></funding-group><funding-group><award-group><funding-source>GlaxoSmithKline</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Janssen</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Merck</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Takeda</funding-source></award-group></funding-group><counts><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12572</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:12.10.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12572-sec-0005"><title>Introduction</title><p id="dom12572-para-0005">Cardiovascular (CV) disease is the major cause of morbidity and mortality in patients with type 2 diabetes (T2DM) <xref rid="dom12572-bib-0001" ref-type="ref">1</xref>. The risk of CV disease in adults with diabetes is double that in adults without diabetes, and diabetes is estimated to account for 10&#x02013;12% of all vascular deaths <xref rid="dom12572-bib-0002" ref-type="ref">2</xref>. Patients with T2DM often have numerous CV risk factors and a multifactorial approach to addressing CV risk, including controlling glycaemia, blood pressure (BP) and body weight, is recommended in these patients <xref rid="dom12572-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12572-bib-0003" ref-type="ref">3</xref>.</p><p id="dom12572-para-0006">The metabolic abnormalities that are characteristic of diabetes, such as hyperglycaemia, excess free fatty acids and insulin resistance, can lead to suppression of nitric oxide production and activation of the renin&#x02010;angiotensin system, leading to oxidative stress, endothelial dysfunction and activation of the receptor for advanced glycation end products (RAGE) <xref rid="dom12572-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12572-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12572-bib-0006" ref-type="ref">6</xref>. These may contribute to hypertension <xref rid="dom12572-bib-0007" ref-type="ref">7</xref> or to increased arterial stiffness related to vascular calcification or accumulation of collagen <xref rid="dom12572-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12572-bib-0009" ref-type="ref">9</xref> that could partly explain the increased risk of vascular complications associated with T2DM <xref rid="dom12572-bib-0004" ref-type="ref">4</xref>.</p><p id="dom12572-para-0007">Arterial stiffness is a strong predictor of CV events, heart failure and death <xref rid="dom12572-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12572-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12572-bib-0012" ref-type="ref">12</xref>. Although aortic pulse wave velocity is generally considered to be the &#x02018;gold standard&#x02019; for non&#x02010;invasive assessments of arterial stiffness, in clinical practice, pulse pressure (PP) can be used as a surrogate marker. PP is determined by cardiac output and the stiffness of elastic central arteries, such as the aorta, and may be calculated as the difference between systolic BP (SBP) and diastolic BP (DBP) <xref rid="dom12572-bib-0013" ref-type="ref">13</xref>. Increased peripheral PP is an independent predictor of CV disease in patients with T2DM <xref rid="dom12572-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12572-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12572-bib-0016" ref-type="ref">16</xref>, and a meta&#x02010;analysis showed that the relative risks of CV events were similar for an increase in central SBP and central PP to those for their peripheral (brachial) counterparts <xref rid="dom12572-bib-0017" ref-type="ref">17</xref>. Another marker of arterial stiffness is the ambulatory arterial stiffness index [AASI: 1 minus the regression slope of DBP and SBP values derived from 24&#x02010;h ambulatory BP monitoring (ABPM) <xref rid="dom12572-bib-0018" ref-type="ref">18</xref>]. The AASI represents the dynamic relationship between SBP and DBP, as defined by haemodynamic arterio&#x02010;ventricular properties, and has been reported to be an independent predictor of CV mortality <xref rid="dom12572-bib-0019" ref-type="ref">19</xref>.</p><p id="dom12572-para-0008">Mean arterial pressure (MAP) is a measure of central haemodynamics that reflects the cardiac cycle and is determined by cardiac output, systemic vascular resistance and central venous pressure. MAP is calculated as 2/3 DBP&#x02009;+&#x02009;1/3 SBP <xref rid="dom12572-bib-0016" ref-type="ref">16</xref> and has been shown to be predictive of CV events in patients with T2DM.</p><p id="dom12572-para-0009">The myocardium's workload is related to vascular stiffness and cardiac function, and one variable that quantifies this is the double product (DP), also known as the rate pressure product (RPP). This is calculated as heart rate&#x02009;&#x000d7;&#x02009;SBP and provides an indirect measure of myocardial oxygen demand. Chronic elevations of DP, representing an increased cardiac load, may cause long&#x02010;term cardiac impairment and DP is associated with CV complications, CV mortality and non&#x02010;CV mortality <xref rid="dom12572-bib-0020" ref-type="ref">20</xref>, <xref rid="dom12572-bib-0021" ref-type="ref">21</xref>.</p><p id="dom12572-para-0010">Empagliflozin is a potent and selective sodium glucose cotransporter 2 (SGLT2) inhibitor <xref rid="dom12572-bib-0022" ref-type="ref">22</xref> used in the treatment of T2DM. In phase III trials, empagliflozin (10 and 25&#x02009;mg) improved glycaemic control with a low risk of hypoglycaemia, and was associated with reductions in BP and body weight <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0025" ref-type="ref">25</xref>, <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>, <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>. In a 4&#x02010;week study in patients with T2DM, empagliflozin monotherapy reduced oxidative stress, as shown by reductions in 8&#x02010;iso&#x02010;prostaglandin2&#x003b1;, and also improved daily blood glucose control <xref rid="dom12572-bib-0028" ref-type="ref">28</xref>. Empagliflozin has been shown to have central haemodynamic effects: in patients with type 1 diabetes (T1DM), empagliflozin reduced arterial stiffness assessed by measurement of carotid&#x02010;radial pulse wave velocity and radial, carotid and aortic augmentation indices <xref rid="dom12572-bib-0029" ref-type="ref">29</xref>.</p><p id="dom12572-para-0011">To determine the effects of empagliflozin on markers of arterial stiffness (PP and AASI) and arterial resistance (MAP) in patients with T2DM, we analysed data from five phase III studies. We also determined the effects of empagliflozin on indirect determinants of myocardial oxygen demand and hence the workload on the heart (heart rate, BP and DP). Further, we conducted subgroup analyses to test our hypothesis that empagliflozin would reduce BP, PP and MAP across subgroups defined by age, sex and degree of hypertension at baseline, with greater reductions in older patients and those with the highest SBP at baseline.</p></sec><sec id="dom12572-sec-0006"><title>Methods</title><sec id="dom12572-sec-0007"><title>Study Design and Patients</title><p id="dom12572-para-0012">Data from two cohorts of patients, one treated with empagliflozin for 12&#x02009;weeks (cohort 1) and one treated with empagliflozin for 24&#x02009;weeks (cohort 2), were analysed. Cohort 1 comprised patients from the EMPA&#x02010;REG BP&#x02122; trial <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>. Patients had T2DM with hypertension (mean seated office SBP 130&#x02013;159&#x02009;mmHg and DBP 80&#x02013;99&#x02009;mmHg), glycated haemoglobin (HbA1c) &#x02265;7 and &#x02264;10% (&#x02265;53 and &#x02264;86&#x02009;mmol/mol) and a body mass index &#x02264;45&#x02009;kg/m<sup>2</sup> at baseline. Patients were either drug&#x02010;naive [had not received any oral glucose&#x02010;lowering therapy, glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) analogue, or insulin for &#x02265;12&#x02009;weeks (&#x02265;16&#x02009;weeks for pioglitazone) before randomization] or had been receiving stable doses of glucose&#x02010;lowering therapy [oral agents or GLP&#x02010;1 analogue at doses unchanged for &#x02265;12&#x02009;weeks (&#x02265;16&#x02009;weeks for pioglitazone) before randomization, or insulin at dose changed by &#x02264;10% for &#x02265;12&#x02009;weeks before randomization] <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>. Patients were required to have been receiving no, one or two BP&#x02010;lowering medications at a stable dose for &#x02265;4&#x02009;weeks at screening and throughout a 2&#x02010;week placebo run&#x02010;in period. Patients were randomized to receive empagliflozin 10&#x02009;mg, empagliflozin 25&#x02009;mg, or placebo once daily for 12&#x02009;weeks. Patients underwent 24&#x02010;h ABPM &#x02264;7&#x02009;days before randomization and at week 12 <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>. During the treatment period, patients continued their background BP&#x02010;lowering therapy at an unchanged dose, but changes in BP&#x02010;lowering medication could be initiated if a patient had a mean SBP &#x02265;160&#x02009;mmHg and/or a mean DBP &#x02265;100&#x02009;mmHg at a clinic visit.</p><p id="dom12572-para-0013">Cohort 2 comprised patients from the four pivotal trials of empagliflozin required for regulatory submissions: EMPA&#x02010;REG MONO&#x02122; <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>, EMPA&#x02010;REG MET&#x02122; <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, EMPA&#x02010;REG METSU&#x02122; <xref rid="dom12572-bib-0025" ref-type="ref">25</xref> and EMPA&#x02010;REG PIO&#x02122; <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>. Patients in these trials had T2DM, HbA1c &#x02265;7 and &#x02264;10% (&#x02265;53 and &#x02264;86&#x02009;mmol/mol) and a body mass index &#x02264;45&#x02009;kg/m<sup>2</sup>. Patients in the EMPA&#x02010;REG MONO&#x02122; trial were drug&#x02010;naive (had not received glucose&#x02010;lowering therapy for &#x02265;12&#x02009;weeks before randomization) <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>. Patients in the EMPA&#x02010;REG MET&#x02122; or EMPA&#x02010;REG METSU&#x02122; trials had received immediate&#x02010;release metformin [&#x02265;1500&#x02009;mg/day, up to maximum tolerated dose (MTD) or maximum dose according to local label] unchanged for &#x02265;12&#x02009;weeks before randomization, or metformin plus a sulphonylurea (&#x02265;50% of MTD, up to the MTD or maximum dose according to local label) unchanged for &#x02265;12&#x02009;weeks before randomization, respectively <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0025" ref-type="ref">25</xref>. Patients in the EMPA&#x02010;REG PIO&#x02122; trial had received pioglitazone (&#x02265;30&#x02009;mg/day, up to MTD or maximum dose according to local label) unchanged for &#x02265;12&#x02009;weeks before randomization, with or without metformin immediate release (as described above) <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>. In all four trials, patients were randomized to receive empagliflozin 10&#x02009;mg, empagliflozin 25&#x02009;mg, or placebo as monotherapy (EMPA&#x02010;REG MONO&#x02122;) or add&#x02010;on to background therapy for 24&#x02009;weeks.</p><p id="dom12572-para-0014">Glucose&#x02010;lowering rescue medication could be initiated at the discretion of the investigator if, after an overnight fast, a patient had a confirmed plasma glucose level &#x0003e;13.3&#x02009;mmol/l during the first 12&#x02009;weeks of treatment or, in the 24&#x02010;week trials, &#x0003e;11.1&#x02009;mmol/l [or HbA1c &#x0003e;8.5% (69&#x02009;mmol/mol) in the EMPA&#x02010;REG MET&#x02122; and EMPA&#x02010;REG METSU&#x02122; studies] during weeks 12&#x02013;24.</p><p id="dom12572-para-0015">All studies were approved by the Institutional Review Boards and Independent Ethics Committees and Competent Authorities of the participating centres and complied with the Declaration of Helsinki in accordance with the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice. All patients who participated in these studies provided written informed consent.</p></sec><sec id="dom12572-sec-0008"><title>Endpoints and Measurements</title><p id="dom12572-para-0016">In the present <italic>post hoc</italic> analysis, the following endpoints were analysed in cohort 1: changes from baseline in HbA1c and in 24&#x02010;h SBP and DBP, heart rate, PP, MAP, DP (or RPP) and AASI (based on 24&#x02010;h ABPM measurements) at week 12. The following endpoints were analysed in cohort 2: changes from baseline in HbA1c, seated office SBP and DBP, heart rate, PP, MAP and DP (or RPP) at week 24.</p><p id="dom12572-para-0017">In both cohorts, changes from baseline in SBP, DBP, PP and MAP were analysed in subgroups of patients by baseline age (&#x0003c;50, 50 to &#x0003c;65, 65 to &#x0003c;75, &#x02265;75&#x02009;years), sex, and baseline SBP (&#x0003c;130, 130&#x02013;140, &#x0003e;140&#x02009;mmHg). PP was calculated as SBP&#x000a0;&#x02013;&#x000a0;DBP (mmHg). MAP was calculated as 2/3 DBP&#x02009;+&#x02009;1/3 SBP (mmHg). DP (or RPP) was calculated as heart rate (bpm)&#x02009;&#x000d7;&#x02009;SBP (mmHg). AASI was calculated as 1 minus the regression slope of DBP on SBP during 24&#x02010;h ABPM.</p><p id="dom12572-para-0018">In light of the small/modest differences in the impact of empagliflozin 10 and 25&#x02009;mg on reducing SBP and DBP <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0025" ref-type="ref">25</xref>, <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>, <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>, the two doses were pooled for the purpose of the present analyses.</p></sec><sec id="dom12572-sec-0009"><title>Statistical Analyses</title><p id="dom12572-para-0019">For each cohort, data from patients in the empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg groups were pooled. Changes from baseline in each cohort were analysed using an analysis of covariance (<sc>ancova</sc>) with baseline HbA1c and the baseline value of the endpoint in question (if not HbA1c) as linear covariates, and baseline estimated glomerular filtration rate (Modification of Diet in Renal Disease equation), region and treatment as fixed effects. The number of BP&#x02010;lowering medications at baseline was an additional fixed effect in analysis of data from cohort 1. In cohort 2, the individual study was an additional fixed effect when analysing the data. Changes from baseline in SBP, DBP, PP and MAP in subgroups of baseline age, sex and baseline SBP were analysed using the same <sc>ancova</sc> model, but including baseline age, sex and baseline SBP, respectively, as additional linear covariates and the corresponding treatment by subgroup of interest interaction. For cohort 1, baseline SBP was the baseline mean 24&#x02010;h SBP value. Analyses were conducted on the full analysis set (FAS). For cohort 1, the FAS comprised randomized patients who received &#x02265;1 dose of study drug and had a baseline HbA1c value and a baseline mean 24&#x02010;h SBP value. For cohort 2, the FAS comprised randomized patients who received &#x02265;1 dose of study drug and had a baseline HbA1c value. Values observed after initiation of glucose&#x02010;lowering rescue therapy were set to missing. A last observation carried forward (LOCF) approach was used to impute missing data. Statistical analyses were performed using % data for HbA1c.</p></sec></sec><sec id="dom12572-sec-0010"><title>Results</title><sec id="dom12572-sec-0011"><title>Patients</title><p id="dom12572-para-0020">Of 825 patients randomized in the EMPA&#x02010;REG BP&#x02122; trial, 823 were included in the FAS for cohort 1 (empagliflozin: n&#x02009;=&#x02009;552; placebo: n&#x02009;=&#x02009;271). Of the 2482 patients randomized in the four 24&#x02010;week phase III trials, 2477 patients were included in the FAS for cohort 2 (empagliflozin: n&#x02009;=&#x02009;1652; placebo: n&#x02009;=&#x02009;825). In each cohort, patient demographics and baseline characteristics were generally balanced between treatment groups (Table S1).</p></sec><sec id="dom12572-sec-0012"><title>Glycaemic Control</title><p id="dom12572-para-0021">In both cohorts, empagliflozin significantly reduced HbA1c from baseline compared with placebo. In cohort 1, the adjusted mean&#x02009;&#x000b1;&#x02009;standard error (s.e.) change from baseline in HbA1c at week 12 was 0.03&#x02009;(&#x000b1;&#x02009;0.04)% [0.3&#x02009;(&#x000b1;&#x02009;0.4)&#x02009;mmol/mol] with placebo compared with &#x02212;0.61&#x02009;(&#x000b1;&#x02009;0.02)% [&#x02212;6.7&#x02009;(&#x000b1;&#x02009;0.3)&#x02009;mmol/mol] with empagliflozin {adjusted mean difference vs placebo: &#x02212;0.64% [95% confidence interval (CI) &#x02212;0.72, &#x02212;0.55] or &#x02212;7.0&#x02009;mmol/mol (95% CI &#x02212;7.9, &#x02212;6.0); p&#x02009;&#x0003c;&#x02009;0.001}. In cohort 2, the adjusted mean&#x02009;(&#x000b1;&#x02009;s.e.) change from baseline in HbA1c at week 24 was &#x02212;0.08&#x02009;(&#x000b1;&#x02009;0.03)% [&#x02212;0.9&#x02009;(&#x000b1;&#x02009;0.3) mmol/mol] with placebo compared with &#x02212;0.73&#x02009;(&#x000b1;&#x02009;0.02)% [&#x02212;8.0&#x02009;(&#x000b1;&#x02009;0.2) mmol/mol] with empagliflozin [adjusted mean difference vs placebo: &#x02212;0.65% (95% CI &#x02212;0.71, &#x02212;0.59) or &#x02212;7.1&#x02009;mmol/mol (95% CI &#x02212;7.8, &#x02212;6.4); p&#x02009;&#x0003c;&#x02009;0.001]. The proportions of patients with imputed data for change from baseline in HbA1c in cohort 1 at week 12 were 10.3 and 9.6% for patients treated with empagliflozin and placebo, respectively, whereas in cohort 2, the corresponding figures at week 24 were 12.2 and 25.7%.</p></sec><sec id="dom12572-sec-0013"><title>Blood Pressure and Heart Rate</title><p id="dom12572-para-0022">In both cohorts, empagliflozin significantly reduced SBP and DBP from baseline compared with placebo. In cohort 1, the adjusted mean difference versus placebo in change from baseline in mean 24&#x02010;h SBP at week 12 was &#x02212;3.9&#x02009;mmHg (95% CI &#x02212;5.0, &#x02212;2.7; p&#x02009;&#x0003c;&#x02009;0.001) and in mean 24&#x02010;h DBP was &#x02212;1.5&#x02009;mmHg (95% CI &#x02212;2.2, &#x02212;0.8; p&#x02009;&#x0003c;&#x02009;0.001; Figure S1). In cohort 2, the adjusted mean difference versus placebo in change from baseline in SBP at week 24 was &#x02212;3.6&#x02009;mmHg (95% CI &#x02212;4.5, &#x02212;2.7; p&#x02009;&#x0003c;&#x02009;0.001) and in DBP was &#x02212;1.3&#x02009;mmHg (95% CI &#x02212;1.9, &#x02212;0.8; p&#x02009;&#x0003c;&#x02009;0.001; Figure S1). The adjusted mean difference versus placebo in change from baseline in mean 24&#x02010;h heart rate was &#x02212;0.6&#x02009;bpm (95% CI &#x02212;1.4, 0.3; p&#x02009;=&#x02009;0.209) in cohort 1 and &#x02212;0.8&#x02009;bpm (95% CI &#x02212;1.4, &#x02212;0.2; p&#x02009;=&#x02009;0.012) in cohort 2 (Figure S1). The proportions of patients with imputed data for change from baseline in SBP in cohort 1 at week 12 were 12.7 and 13.3% for patients treated with empagliflozin and placebo, respectively, whereas in cohort 2, the corresponding figures at week 24 were 11.6 and 25.1%.</p></sec><sec id="dom12572-sec-0014"><title>Markers of Arterial Stiffness and Vascular Resistance</title><p id="dom12572-para-0023">Empagliflozin significantly (p&#x02009;&#x0003c;&#x02009;0.001) reduced PP, MAP and DP (or RPP) compared with placebo in both cohorts (Figure <xref rid="dom12572-fig-0001" ref-type="fig">1</xref>). In cohort 1, the reduction in AASI did not reach significance (p&#x02009;=&#x02009;0.059 for differences vs placebo).</p><fig fig-type="Figure" xml:lang="en" id="dom12572-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Changes in markers of arterial stiffness and vascular resistance. (A) Change from baseline in pulse pressure (<styled-content style="fixed-case">PP</styled-content>) at week 12 in cohort 1 and week 24 in cohort 2 [analysis of covariance (<sc>ancova</sc>) using last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>)]. (B) Change from baseline in mean arterial pressure (<styled-content style="fixed-case">MAP</styled-content>) at week 12 in cohort 1 and week 24 in cohort 2 (<sc>ancova</sc>, <styled-content style="fixed-case">LOCF</styled-content>). (C) Change from baseline in double product (<styled-content style="fixed-case">DP</styled-content>) or rate pressure product (<styled-content style="fixed-case">RPP</styled-content>) at week 12 in cohort 1 and week 24 in cohort 2 (<sc>ancova</sc>, <styled-content style="fixed-case">LOCF</styled-content>). (D) Change from baseline in ambulatory arterial stiffness index (<styled-content style="fixed-case">AASI</styled-content>) at week 12 in cohort 1. Data are adjusted mean&#x02009;&#x000b1;&#x02009;standard error (s.e.) in the full analysis set. In cohort 1, measurements were based on mean 24&#x02010;h <styled-content style="fixed-case">ABPM</styled-content> and in cohort 2, they were based on seated office measurements.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-17-1180-g001"><alt-text>DOM-12572-FIG-001a-b</alt-text></graphic></fig><sec id="dom12572-sec-0015"><title>
<styled-content style="italic-in-any-context">Subgroup Analyses: Baseline Age</styled-content>
</title><p id="dom12572-para-0024">With increasing age, baseline SBP generally increased and baseline DBP generally decreased, hence baseline PP increased (Figure <xref rid="dom12572-fig-0002" ref-type="fig">2</xref>). Empagliflozin reduced SBP, DBP, PP and MAP compared with placebo in most subgroups by baseline age; however, none of the interaction p values reached significance (p&#x02009;&#x0003c;&#x02009;0.1) except for PP in cohort 2, which was reduced to a greater extent in older patients (p&#x02009;=&#x02009;0.011; Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12572-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>), diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>), pulse pressure (<styled-content style="fixed-case">PP</styled-content>) and mean arterial pressure (<styled-content style="fixed-case">MAP</styled-content>) by subgroups of baseline age. (A) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline and at week 12 in cohort 1. (B) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline at week 24 in cohort 2. Baseline data are mean&#x02009;&#x000b1;&#x02009;standard error (s.e.), week 12 or 24 data are adjusted mean&#x02009;&#x000b1;&#x02009;s.e. based on analysis of covariance (<sc>ancova</sc>) in the full analysis set using last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>) imputation. In cohort 1, measurements were based on mean 24&#x02010;h ambulatory blood pressure monitoring (<styled-content style="fixed-case">ABPM</styled-content>) and in cohort 2, they were based on seated office measurements. ***p&#x02009;&#x0003c;&#x02009;0.001, **p&#x02009;&#x0003c;&#x02009;0.01 and *p&#x02009;&#x0003c;&#x02009;0.05 for adjusted mean differences for empagliflozin versus placebo in change from baseline based on <sc>ancova</sc> with <styled-content style="fixed-case">LOCF</styled-content> imputation.</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-17-1180-g002"><alt-text>DOM-12572-FIG-002a-b</alt-text></graphic></fig><table-wrap id="dom12572-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Subgroup analyses of differences between empagliflozin and placebo in changes from baseline in markers of arterial stiffness and vascular resistance.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th style="border-bottom:solid 1px #000000" rowspan="2" id="dom12572-ent-0001" align="left" valign="bottom" colspan="1">Subgroup</th><th id="dom12572-ent-0002" align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th id="dom12572-ent-0003" align="left" valign="bottom" rowspan="1" colspan="1">Empagliflozin</th><th style="border-bottom:solid 1px #000000" colspan="4" align="left" id="dom12572-ent-0004" valign="bottom" rowspan="1">Adjusted mean (95% CI) differences for empagliflozin vs placebo in change from baseline in:</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12572-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">n</th><th id="dom12572-ent-0006" align="left" valign="bottom" rowspan="1" colspan="1">n</th><th id="dom12572-ent-0007" align="left" valign="bottom" rowspan="1" colspan="1">SBP, mmHg</th><th id="dom12572-ent-0008" align="left" valign="bottom" rowspan="1" colspan="1">DBP, mmHg</th><th id="dom12572-ent-0009" align="left" valign="bottom" rowspan="1" colspan="1">PP, mmHg</th><th id="dom12572-ent-0010" align="left" valign="bottom" rowspan="1" colspan="1">MAP, mmHg</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" id="dom12572-ent-0011" valign="top" rowspan="1">
<bold>Cohort 1</bold>
</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0012" valign="top" rowspan="1">
<bold>Baseline age</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0013" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;50&#x02009;years</td><td rowspan="2" id="dom12572-ent-0014" align="left" valign="top" colspan="1">31</td><td rowspan="2" id="dom12572-ent-0015" align="left" valign="top" colspan="1">65</td><td id="dom12572-ent-0016" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.5 (&#x02212;7.0, &#x02212;0.0)</td><td id="dom12572-ent-0017" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;3.6, 0.4)</td><td id="dom12572-ent-0018" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;4.0, 0.4)</td><td id="dom12572-ent-0019" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;4.6, 0.1)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0020" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.050</td><td id="dom12572-ent-0021" align="left" valign="top" rowspan="1" colspan="1">0.111</td><td id="dom12572-ent-0022" align="left" valign="top" rowspan="1" colspan="1">0.105</td><td id="dom12572-ent-0023" align="left" valign="top" rowspan="1" colspan="1">0.063</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0024" align="left" valign="top" rowspan="1" colspan="1">50 to &#x0003c;65&#x02009;years</td><td rowspan="2" id="dom12572-ent-0025" align="left" valign="top" colspan="1">154</td><td rowspan="2" id="dom12572-ent-0026" align="left" valign="top" colspan="1">313</td><td id="dom12572-ent-0027" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.3 (&#x02212;5.8, &#x02212;2.7)</td><td id="dom12572-ent-0028" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.6, &#x02212;0.8)</td><td id="dom12572-ent-0029" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;3.4, &#x02212;1.5)</td><td id="dom12572-ent-0030" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;3.7, &#x02212;1.5)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0031" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0032" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0033" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0034" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0035" align="left" valign="top" rowspan="1" colspan="1">65 to &#x0003c;75&#x02009;years</td><td rowspan="2" id="dom12572-ent-0036" align="left" valign="top" colspan="1">79</td><td rowspan="2" id="dom12572-ent-0037" align="left" valign="top" colspan="1">136</td><td id="dom12572-ent-0038" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.1 (&#x02212;5.4, &#x02212;0.9)</td><td id="dom12572-ent-0039" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.2 (&#x02212;2.5, 0.1)</td><td id="dom12572-ent-0040" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.0 (&#x02212;3.4. &#x02212;0.6)</td><td id="dom12572-ent-0041" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;3.4, &#x02212;0.3)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0042" align="left" valign="top" rowspan="1" colspan="1">0.006</td><td id="dom12572-ent-0043" align="left" valign="top" rowspan="1" colspan="1">0.073</td><td id="dom12572-ent-0044" align="left" valign="top" rowspan="1" colspan="1">0.006</td><td id="dom12572-ent-0045" align="left" valign="top" rowspan="1" colspan="1">0.018</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0046" align="left" valign="top" rowspan="1" colspan="1">&#x02265;75&#x02009;years</td><td rowspan="2" id="dom12572-ent-0047" align="left" valign="top" colspan="1">7</td><td rowspan="2" id="dom12572-ent-0048" align="left" valign="top" colspan="1">38</td><td id="dom12572-ent-0049" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.4 (&#x02212;11.0, 2.2)</td><td id="dom12572-ent-0050" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;4.4, 3.2)</td><td id="dom12572-ent-0051" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.4 (&#x02212;8.5, &#x02212;0.4)</td><td id="dom12572-ent-0052" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;6.2, 2.8)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0053" align="left" valign="top" rowspan="1" colspan="1">0.189</td><td id="dom12572-ent-0054" align="left" valign="top" rowspan="1" colspan="1">0.748</td><td id="dom12572-ent-0055" align="left" valign="top" rowspan="1" colspan="1">0.033</td><td id="dom12572-ent-0056" align="left" valign="top" rowspan="1" colspan="1">0.462</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0057" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0058" align="left" valign="top" rowspan="1" colspan="1">0.865</td><td id="dom12572-ent-0059" align="left" valign="top" rowspan="1" colspan="1">0.874</td><td id="dom12572-ent-0060" align="left" valign="top" rowspan="1" colspan="1">0.665</td><td id="dom12572-ent-0061" align="left" valign="top" rowspan="1" colspan="1">0.881</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0062" valign="top" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0063" align="left" valign="top" rowspan="1" colspan="1">Male</td><td rowspan="2" id="dom12572-ent-0064" align="left" valign="top" colspan="1">168</td><td rowspan="2" id="dom12572-ent-0065" align="left" valign="top" colspan="1">327</td><td id="dom12572-ent-0066" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.7 (&#x02212;5.2, &#x02212;2.1)</td><td id="dom12572-ent-0067" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.3 (&#x02212;2.1, &#x02212;0.4)</td><td id="dom12572-ent-0068" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;3.3, &#x02212;1.4)</td><td id="dom12572-ent-0069" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;3.1, &#x02212;1.0)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0070" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0071" align="left" valign="top" rowspan="1" colspan="1">0.005</td><td id="dom12572-ent-0072" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0073" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0074" align="left" valign="top" rowspan="1" colspan="1">Female</td><td rowspan="2" id="dom12572-ent-0075" align="left" valign="top" colspan="1">103</td><td rowspan="2" id="dom12572-ent-0076" align="left" valign="top" colspan="1">225</td><td id="dom12572-ent-0077" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.2 (&#x02212;6.0, &#x02212;2.3)</td><td id="dom12572-ent-0078" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;3.0, &#x02212;0.8)</td><td id="dom12572-ent-0079" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;3.4, &#x02212;1.0)</td><td id="dom12572-ent-0080" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.7 (&#x02212;4.0, &#x02212;1.4)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0081" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0082" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0083" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0084" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0085" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0086" align="left" valign="top" rowspan="1" colspan="1">0.681</td><td id="dom12572-ent-0087" align="left" valign="top" rowspan="1" colspan="1">0.379</td><td id="dom12572-ent-0088" align="left" valign="top" rowspan="1" colspan="1">0.875</td><td id="dom12572-ent-0089" align="left" valign="top" rowspan="1" colspan="1">0.461</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0090" valign="top" rowspan="1">
<bold>Baseline SBP</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0091" align="left" valign="top" rowspan="1" colspan="1">SBP&#x02009;&#x0003c;130&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0092" align="left" valign="top" colspan="1">130</td><td rowspan="2" id="dom12572-ent-0093" align="left" valign="top" colspan="1">276</td><td id="dom12572-ent-0094" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;4.1, &#x02212;0.7)</td><td id="dom12572-ent-0095" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;2.1, &#x02212;0.1)</td><td id="dom12572-ent-0096" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;2.5, &#x02212;0.4)</td><td id="dom12572-ent-0097" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.8, &#x02212;0.5)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0098" align="left" valign="top" rowspan="1" colspan="1">0.006</td><td id="dom12572-ent-0099" align="left" valign="top" rowspan="1" colspan="1">0.024</td><td id="dom12572-ent-0100" align="left" valign="top" rowspan="1" colspan="1">0.007</td><td id="dom12572-ent-0101" align="left" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0102" align="left" valign="top" rowspan="1" colspan="1">SBP 130&#x02013;140&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0103" align="left" valign="top" colspan="1">85</td><td rowspan="2" id="dom12572-ent-0104" align="left" valign="top" colspan="1">147</td><td id="dom12572-ent-0105" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.9 (&#x02212;7.1, &#x02212;2.7)</td><td id="dom12572-ent-0106" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;3.3, &#x02212;0.8)</td><td id="dom12572-ent-0107" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.9 (&#x02212;4.2, &#x02212;1.5)</td><td id="dom12572-ent-0108" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.0 (&#x02212;4.5, &#x02212;1.6)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0109" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0110" align="left" valign="top" rowspan="1" colspan="1">0.001</td><td id="dom12572-ent-0111" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0112" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0113" align="left" valign="top" rowspan="1" colspan="1">SBP &#x0003e;140&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0114" align="left" valign="top" colspan="1">56</td><td rowspan="2" id="dom12572-ent-0115" align="left" valign="top" colspan="1">129</td><td id="dom12572-ent-0116" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.6 (&#x02212;7.3, &#x02212;2.0)</td><td id="dom12572-ent-0117" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;2.9, 0.1)</td><td id="dom12572-ent-0118" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.2 (&#x02212;4.8, &#x02212;1.7)</td><td id="dom12572-ent-0119" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;4.2, &#x02212;0.7)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0120" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0121" align="left" valign="top" rowspan="1" colspan="1">0.059</td><td id="dom12572-ent-0122" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0123" align="left" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0124" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0125" align="left" valign="top" rowspan="1" colspan="1">0.153</td><td id="dom12572-ent-0126" align="left" valign="top" rowspan="1" colspan="1">0.494</td><td id="dom12572-ent-0127" align="left" valign="top" rowspan="1" colspan="1">0.092</td><td id="dom12572-ent-0128" align="left" valign="top" rowspan="1" colspan="1">0.342</td></tr><tr><td colspan="7" align="left" id="dom12572-ent-0129" valign="top" rowspan="1">
<bold>Cohort 2</bold>
</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0130" valign="top" rowspan="1">
<bold>Baseline age</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0131" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;50&#x02009;years</td><td rowspan="2" id="dom12572-ent-0132" align="left" valign="top" colspan="1">222</td><td rowspan="2" id="dom12572-ent-0133" align="left" valign="top" colspan="1">464</td><td id="dom12572-ent-0134" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.3 (&#x02212;5.0, &#x02212;1.5)</td><td id="dom12572-ent-0135" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;2.2, 0.0)</td><td id="dom12572-ent-0136" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;3.5, &#x02212;0.8)</td><td id="dom12572-ent-0137" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;3.0, &#x02212;0.6)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0138" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0139" align="left" valign="top" rowspan="1" colspan="1">0.053</td><td id="dom12572-ent-0140" align="left" valign="top" rowspan="1" colspan="1">0.002</td><td id="dom12572-ent-0141" align="left" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0142" align="left" valign="top" rowspan="1" colspan="1">50 to &#x0003c;65&#x02009;years</td><td rowspan="2" id="dom12572-ent-0143" align="left" valign="top" colspan="1">459</td><td rowspan="2" id="dom12572-ent-0144" align="left" valign="top" colspan="1">871</td><td id="dom12572-ent-0145" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.4 (&#x02212;4.6, &#x02212;2.2)</td><td id="dom12572-ent-0146" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;2.6, &#x02212;1.0)</td><td id="dom12572-ent-0147" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;2.6, &#x02212;0.6)</td><td id="dom12572-ent-0148" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;3.2, &#x02212;1.5)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0149" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0150" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0151" align="left" valign="top" rowspan="1" colspan="1">0.001</td><td id="dom12572-ent-0152" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0153" align="left" valign="top" rowspan="1" colspan="1">65 to &#x0003c;75&#x02009;years</td><td rowspan="2" id="dom12572-ent-0154" align="left" valign="top" colspan="1">119</td><td rowspan="2" id="dom12572-ent-0155" align="left" valign="top" colspan="1">276</td><td id="dom12572-ent-0156" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.0 (&#x02212;6.3, &#x02212;1.6)</td><td id="dom12572-ent-0157" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;1.8, 1.1)</td><td id="dom12572-ent-0158" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.6 (&#x02212;5.5. &#x02212;1.8)</td><td id="dom12572-ent-0159" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;3.2, 0.0)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0160" align="left" valign="top" rowspan="1" colspan="1">0.001</td><td id="dom12572-ent-0161" align="left" valign="top" rowspan="1" colspan="1">0.649</td><td id="dom12572-ent-0162" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0163" align="left" valign="top" rowspan="1" colspan="1">0.053</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0164" align="left" valign="top" rowspan="1" colspan="1">&#x02265;75&#x02009;years</td><td rowspan="2" id="dom12572-ent-0165" align="left" valign="top" colspan="1">25</td><td rowspan="2" id="dom12572-ent-0166" align="left" valign="top" colspan="1">41</td><td id="dom12572-ent-0167" align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.3 (&#x02212;13.7, &#x02212;2.9)</td><td id="dom12572-ent-0168" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;3.5, 3.3)</td><td id="dom12572-ent-0169" align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.2 (&#x02212;12.4, &#x02212;3.9)</td><td id="dom12572-ent-0170" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.8 (&#x02212;6.5, 0.9)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0171" align="left" valign="top" rowspan="1" colspan="1">0.003</td><td id="dom12572-ent-0172" align="left" valign="top" rowspan="1" colspan="1">0.955</td><td id="dom12572-ent-0173" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0174" align="left" valign="top" rowspan="1" colspan="1">0.135</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0175" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0176" align="left" valign="top" rowspan="1" colspan="1">0.365</td><td id="dom12572-ent-0177" align="left" valign="top" rowspan="1" colspan="1">0.284</td><td id="dom12572-ent-0178" align="left" valign="top" rowspan="1" colspan="1">0.011</td><td id="dom12572-ent-0179" align="left" valign="top" rowspan="1" colspan="1">0.788</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0180" valign="top" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0181" align="left" valign="top" rowspan="1" colspan="1">Male</td><td rowspan="2" id="dom12572-ent-0182" align="left" valign="top" colspan="1">424</td><td rowspan="2" id="dom12572-ent-0183" align="left" valign="top" colspan="1">927</td><td id="dom12572-ent-0184" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.8 (&#x02212;5.1, &#x02212;2.6)</td><td id="dom12572-ent-0185" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.5 (&#x02212;2.3, &#x02212;0.7)</td><td id="dom12572-ent-0186" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;3.3, &#x02212;1.3)</td><td id="dom12572-ent-0187" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;3.2, &#x02212;1.5)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0188" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0189" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0190" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0191" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0192" align="left" valign="top" rowspan="1" colspan="1">Female</td><td rowspan="2" id="dom12572-ent-0193" align="left" valign="top" colspan="1">401</td><td rowspan="2" id="dom12572-ent-0194" align="left" valign="top" colspan="1">725</td><td id="dom12572-ent-0195" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.4 (&#x02212;4.7, &#x02212;2.0)</td><td id="dom12572-ent-0196" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.2 (&#x02212;2.0, &#x02212;0.3)</td><td id="dom12572-ent-0197" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;3.2, &#x02212;1.1)</td><td id="dom12572-ent-0198" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;2.8, &#x02212;1.0)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0199" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0200" align="left" valign="top" rowspan="1" colspan="1">0.006</td><td id="dom12572-ent-0201" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0202" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0203" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0204" align="left" valign="top" rowspan="1" colspan="1">0.598</td><td id="dom12572-ent-0205" align="left" valign="top" rowspan="1" colspan="1">0.546</td><td id="dom12572-ent-0206" align="left" valign="top" rowspan="1" colspan="1">0.851</td><td id="dom12572-ent-0207" align="left" valign="top" rowspan="1" colspan="1">0.526</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12572-ent-0208" valign="top" rowspan="1">
<bold>Baseline SBP</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0209" align="left" valign="top" rowspan="1" colspan="1">SBP&#x02009;&#x0003c;130&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0210" align="left" valign="top" colspan="1">462</td><td rowspan="2" id="dom12572-ent-0211" align="left" valign="top" colspan="1">891</td><td id="dom12572-ent-0212" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;3.9, &#x02212;1.3)</td><td id="dom12572-ent-0213" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;1.6, &#x02212;0.1)</td><td id="dom12572-ent-0214" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.7, &#x02212;0.7)</td><td id="dom12572-ent-0215" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;2.2, &#x02212;0.6)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0216" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0217" align="left" valign="top" rowspan="1" colspan="1">0.033</td><td id="dom12572-ent-0218" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0219" align="left" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0220" align="left" valign="top" rowspan="1" colspan="1">SBP 130&#x02013;140&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0221" align="left" valign="top" colspan="1">201</td><td rowspan="2" id="dom12572-ent-0222" align="left" valign="top" colspan="1">412</td><td id="dom12572-ent-0223" align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.0 (&#x02212;5.9, &#x02212;2.1)</td><td id="dom12572-ent-0224" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.8, &#x02212;0.5)</td><td id="dom12572-ent-0225" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;3.9, &#x02212;0.9)</td><td id="dom12572-ent-0226" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;3.7, &#x02212;1.2)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0227" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0228" align="left" valign="top" rowspan="1" colspan="1">0.005</td><td id="dom12572-ent-0229" align="left" valign="top" rowspan="1" colspan="1">0.001</td><td id="dom12572-ent-0230" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:15%" id="dom12572-ent-0231" align="left" valign="top" rowspan="1" colspan="1">SBP &#x0003e;140&#x02009;mmHg</td><td rowspan="2" id="dom12572-ent-0232" align="left" valign="top" colspan="1">162</td><td rowspan="2" id="dom12572-ent-0233" align="left" valign="top" colspan="1">349</td><td id="dom12572-ent-0234" align="left" valign="top" rowspan="1" colspan="1">&#x02212;6.3 (&#x02212;8.4, &#x02212;4.2)</td><td id="dom12572-ent-0235" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;3.6, &#x02212;1.1)</td><td id="dom12572-ent-0236" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.6 (&#x02212;5.3, &#x02212;2.0)</td><td id="dom12572-ent-0237" align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.5 (&#x02212;4.9, &#x02212;2.2)</td></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">p value</td><td id="dom12572-ent-0238" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0239" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0240" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12572-ent-0241" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="3" align="left" id="dom12572-ent-0242" valign="top" rowspan="1">Interaction p value</td><td id="dom12572-ent-0243" align="left" valign="top" rowspan="1" colspan="1">0.013</td><td id="dom12572-ent-0244" align="left" valign="top" rowspan="1" colspan="1">0.123</td><td id="dom12572-ent-0245" align="left" valign="top" rowspan="1" colspan="1">0.124</td><td id="dom12572-ent-0246" align="left" valign="top" rowspan="1" colspan="1">0.027</td></tr></tbody></table><table-wrap-foot><fn id="dom12572-note-0001"><p>
<styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DBP</styled-content>, diastolic blood pressure; <styled-content style="fixed-case">MAP</styled-content>, mean arterial pressure; <styled-content style="fixed-case">PP</styled-content>, pulse pressure; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure.</p></fn><fn id="dom12572-note-0002"><p>Data are adjusted mean (95% <styled-content style="fixed-case">CI</styled-content>) using analysis of covariance (ANCOVA) with <styled-content style="fixed-case">LOCF</styled-content> imputation in randomized patients who received &#x02265;1 dose of study medication and had a baseline <styled-content style="fixed-case">G</styled-content>lycated haemoglobin value (both cohorts) and baseline mean 24&#x02010;h <styled-content style="fixed-case">SBP</styled-content> value (cohort 1 only). Measurements were based on mean 24&#x02010;h <styled-content style="fixed-case">ABPM</styled-content> in cohort 1 and seated office measurements in cohort 2. Data after initiation of glucose&#x02010;lowering rescue therapy were set to missing.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12572-sec-0016"><title>
<styled-content style="italic-in-any-context">Subgroup Analyses: Sex</styled-content>
</title><p id="dom12572-para-0025">In cohort 1, baseline SBP and DBP were higher in men than women (Figure <xref rid="dom12572-fig-0003" ref-type="fig">3</xref>). In cohort 2, baseline SBP was higher in men than women (Figure <xref rid="dom12572-fig-0003" ref-type="fig">3</xref>). Empagliflozin significantly reduced SBP, DBP, PP and MAP compared with placebo in both sexes (Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>; Figure <xref rid="dom12572-fig-0003" ref-type="fig">3</xref>), with no significant interactions between sex and treatment responses.</p><fig fig-type="Figure" xml:lang="en" id="dom12572-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>), diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>), pulse pressure (<styled-content style="fixed-case">PP</styled-content>) and mean arterial pressure (<styled-content style="fixed-case">MAP</styled-content>) by sex. (A) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline and at week 12 in cohort 1. (B) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline and at week 24 in cohort 2. Baseline data are mean&#x02009;&#x000b1;&#x02009;standard error (s.e.), week 12 or 24 data are adjusted mean&#x02009;&#x000b1;&#x02009;s.e. based on analysis of covariance (<sc>ancova</sc>) in the full analysis set using last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>) imputation. In cohort 1, measurements were based on mean 24&#x02010;h ambulatory blood pressure monitoring (<styled-content style="fixed-case">ABPM</styled-content>) and in cohort 2, they were based on seated office measurements. ***p&#x02009;&#x0003c;&#x02009;0.001, **p&#x02009;&#x0003c;&#x02009;0.01 and *p&#x02009;&#x0003c;&#x02009;0.05 for adjusted mean differences for empagliflozin versus placebo in change from baseline based on <sc>ancova</sc> with <styled-content style="fixed-case">LOCF</styled-content> imputation.</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-17-1180-g003"><alt-text>DOM-12572-FIG-003a-b</alt-text></graphic></fig></sec><sec id="dom12572-sec-0017"><title>
<styled-content style="italic-in-any-context">Subgroup Analyses: Baseline <styled-content style="fixed-case">SBP</styled-content></styled-content>
</title><p id="dom12572-para-0026">Baseline DBP, PP and MAP increased with baseline SBP and empagliflozin significantly reduced SBP compared with placebo in all subgroups (Figure <xref rid="dom12572-fig-0004" ref-type="fig">4</xref>), with significant treatment by baseline SBP interaction in cohort 2 (p&#x02009;=&#x02009;0.013; Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>; Figure <xref rid="dom12572-fig-0004" ref-type="fig">4</xref>). Empagliflozin also significantly reduced DBP, PP and MAP in all baseline SBP subgroups, except for DBP in patients with baseline SBP &#x0003e;140&#x02009;mmHg in cohort 1 (Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>; Figure <xref rid="dom12572-fig-0004" ref-type="fig">4</xref>). There appeared to be greater reductions in PP with increasing baseline SBP in both cohorts, although the treatment by baseline SBP interaction only reached significance in cohort 1 (p&#x02009;=&#x02009;0.092 for treatment by baseline SBP interaction; Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>). In cohort 2, there were greater reductions in MAP with increasing baseline SBP (p&#x02009;=&#x02009;0.027 for treatment by baseline SBP interaction; Table <xref rid="dom12572-tbl-0001" ref-type="table-wrap">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12572-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>), diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>), pulse pressure (<styled-content style="fixed-case">PP</styled-content>) and mean arterial pressure (<styled-content style="fixed-case">MAP</styled-content>) by subgroups of baseline <styled-content style="fixed-case">SBP</styled-content>. (A) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline and at week 12 in cohort 1. (B) <styled-content style="fixed-case">SBP</styled-content>, <styled-content style="fixed-case">DBP</styled-content>, <styled-content style="fixed-case">PP</styled-content> and <styled-content style="fixed-case">MAP</styled-content> at baseline and at week 24 in cohort 2. Baseline data are mean&#x02009;&#x000b1;&#x02009;standard error (s.e.), week 12 or 24 data are adjusted mean&#x02009;&#x000b1;&#x02009;s.e. based on analysis of covariance (<sc>ancova</sc>) in the full analysis set using last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>) imputation. In cohort 1, measurements were based on mean 24&#x02010;h ambulatory blood pressure monitoring (<styled-content style="fixed-case">ABPM</styled-content>) and in cohort 2, they were based on seated office measurements. ***p&#x02009;&#x0003c;&#x02009;0.001, **p&#x02009;&#x0003c;&#x02009;0.01 and *p&#x02009;&#x0003c;&#x02009;0.05 for adjusted mean differences for empagliflozin versus placebo in change from baseline based on <sc>ancova</sc> with <styled-content style="fixed-case">LOCF</styled-content> imputation.</p></caption><graphic id="nlm-graphic-7" xlink:href="DOM-17-1180-g004"><alt-text>DOM-12572-FIG-004a-b</alt-text></graphic></fig></sec></sec><sec id="dom12572-sec-0018"><title>Safety and Tolerability</title><p id="dom12572-para-0027">Data on the safety and tolerability of empagliflozin, including adverse events and changes in lipids and other laboratory variables, have been published for the individual trials <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0025" ref-type="ref">25</xref>, <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>, <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>. In brief, empagliflozin was associated with an incidence of hypoglycaemia similar to placebo except when used in combination with a sulphonylurea. Events consistent with genital infection were reported in a higher proportion of patients receiving empagliflozin than placebo, while events consistent with urinary tract infection were reported by a similar proportion of patients receiving empagliflozin and placebo. Events consistent with volume depletion were reported in 1 patient (0.4%) on placebo and 1 patient on empagliflozin (0.2%) in cohort 1, and 2 patients (0.2%) on placebo and 5 patients (0.3%) on empagliflozin in cohort 2; none of these events was reported in patients aged &#x02265;75&#x02009;years. Increases in HDL cholesterol with empagliflozin versus placebo were reported in four of the five studies <xref rid="dom12572-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0025" ref-type="ref">25</xref>, <xref rid="dom12572-bib-0026" ref-type="ref">26</xref>, and two studies reported increases in LDL cholesterol with empagliflozin versus placebo <xref rid="dom12572-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12572-bib-0027" ref-type="ref">27</xref>.</p></sec></sec><sec id="dom12572-sec-0019"><title>Discussion</title><p id="dom12572-para-0028">The objective of the present <italic>post hoc</italic> analysis was to explore the effects of empagliflozin on BP, arterial stiffness and vascular resistance in patients with T2DM. In both of the cohorts studied, empagliflozin reduced BP, without increasing heart rate, and had favourable effects on markers of arterial stiffness and vascular resistance as well as on a marker of myocardial workload.</p><p id="dom12572-para-0029">The differences in baseline SBP, DBP and PP with increasing age were, as expected, based on population data. After the age of 50&#x02009;years, SBP continues to increase, while DBP tends to remain fairly stable between ages 50 and 60&#x02009;years and then decrease, leading to a widening PP <xref rid="dom12572-bib-0030" ref-type="ref">30</xref>. These changes suggest that large artery stiffness becomes the predominant haemodynamic factor driving increases in SBP in individuals aged&#x02009;&#x0003e;60&#x02009;years, while peripheral vascular resistance drives BP in younger individuals <xref rid="dom12572-bib-0030" ref-type="ref">30</xref>.</p><p id="dom12572-para-0030">As we hypothesized, the greatest reductions in PP were observed in the oldest patients and in those with the highest SBP at baseline. MAP was reduced in all the subgroups, with no greater reduction in patients with higher age or SBP at baseline. This is explained by the dominance of DBP in the measurement of MAP, which means that MAP reflects small artery resistance and cardiac output to a greater extent than PP. It appears, therefore, that empagliflozin is efficacious across the entire age range but its effects may differ with age; for example, in younger patients, BP reduction may be mediated via effects on small artery resistance and, in the elderly, largely via effects on large artery stiffness. The reduction in the DP (or RPP), a marker of cardiac workload, observed with empagliflozin was driven by reduction in SBP; empagliflozin had a neutral effect on heart rate in this analysis, consistent with the results of previous trials in patients with T2DM and with the results of a study on the effects of empagliflozin on heart rate variability in patients with T1DM <xref rid="dom12572-bib-0029" ref-type="ref">29</xref>. The reduction in the DP (or RPP) is intriguing from the perspective of its prognostic impact on CV and total mortality, but also from a congestive heart failure perspective, and it is tempting to speculate that empagliflozin may reduce hospitalization for heart failure. Interestingly, in a 16&#x02010;week study in a diabetic hypertensive rat model of heart failure, empagliflozin was observed to have beneficial effects on cardiac morphology and function <xref rid="dom12572-bib-0031" ref-type="ref">31</xref>.</p><p id="dom12572-para-0031">The observation that empagliflozin has an impact on the vasculature without increasing pulse rate is interesting from a CV perspective and could be interpreted as a consequence of a relative reduction in the sympathetic nervous system tonus. Although neurohormonal factors could also play a role, this notion is supported by mechanistic data from normotensive patients with T2DM in whom no apparent changes in muscle sympathetic nerve activity, measured using microneurography, were observed, despite clinical benefits with regard to BP and weight <xref rid="dom12572-bib-0032" ref-type="ref">32</xref>.</p><p id="dom12572-para-0032">Reductions in SBP and DBP have consistently been observed with the use of SGLT2 inhibitors in patients with T2DM <xref rid="dom12572-bib-0033" ref-type="ref">33</xref>, but no data in humans have been published on reductions in arterial stiffness or vascular resistance with SGLT2 inhibitors other than empagliflozin. As no other classes of glucose&#x02010;lowering drugs, including dipeptidyl peptidase&#x02010;4 inhibitors and GLP&#x02010;1 receptor analogues, have shown similar findings, the observed improvements in arterial stiffness and vascular resistance could be a unique phenomenon for empagliflozin, which could have major implications for vascular health and CV prognosis.</p><p id="dom12572-para-0033">The mechanisms by which empagliflozin reduces BP and arterial stiffness are not fully understood, but may be related to improved glycaemic control, weight loss, volume contraction as a result of osmotic diuresis or reduced oxidative stress <xref rid="dom12572-bib-0029" ref-type="ref">29</xref>, <xref rid="dom12572-bib-0033" ref-type="ref">33</xref>, <xref rid="dom12572-bib-0034" ref-type="ref">34</xref>, <xref rid="dom12572-bib-0035" ref-type="ref">35</xref>, <xref rid="dom12572-bib-0036" ref-type="ref">36</xref>. In a rat model, empagliflozin was further shown to normalize endothelial function, reduce oxidative stress in aortic vessels, reverse a pro&#x02010;inflammatory phenotype, and improve AGE/RAGE signalling <xref rid="dom12572-bib-0037" ref-type="ref">37</xref>, all pathways of potential importance to a reduction in arterial stiffness <xref rid="dom12572-bib-0036" ref-type="ref">36</xref>. In addition, in a mouse model of obesity and T2DM, empagliflozin ameliorated pericoronary arterial fibrosis, coronary arterial thickening and cardiac macrophage infiltration, effects that are associated with attenuation of oxidative stress in CV tissue <xref rid="dom12572-bib-0038" ref-type="ref">38</xref>.</p><p id="dom12572-para-0034">In this analysis, events consistent with volume depletion were rare and no such events were reported in patients aged &#x02265;75&#x02009;years; however, the potential for volume depletion in vulnerable patients such as the elderly, those with renal impairment, those with low SBP and those receiving diuretics is acknowledged in the prescribing information for SGLT2 inhibitors <xref rid="dom12572-bib-0039" ref-type="ref">39</xref>, <xref rid="dom12572-bib-0040" ref-type="ref">40</xref>, <xref rid="dom12572-bib-0041" ref-type="ref">41</xref> and appropriate caution should be exercised in the use of empagliflozin in such patients in clinical practice.</p><p id="dom12572-para-0035">Strengths of the analyses presented in this manuscript include the large number of patients analysed (cohort 2) and the use of 24&#x02010;h ABPM in patients with hypertension (cohort 1). Limitations include the <italic>post hoc</italic> nature of the analyses, the relatively small number of patients in the older age groups, that the analyses did not account for multiple testing, and the short exposure period to the drug (12 or 24&#x02009;weeks). In addition, there were few Asian patients with advanced hypertension, which limits the generalizability of our findings to this population.</p><p id="dom12572-para-0036">Indirect evidence suggests that reductions in arterial stiffness and vascular resistance may reduce CV risk beyond BP reduction <xref rid="dom12572-bib-0042" ref-type="ref">42</xref>, <xref rid="dom12572-bib-0043" ref-type="ref">43</xref>. Reductions in BP and arterial stiffness are two of the effects of SGLT2 inhibitors that might ameliorate CV risk and heart failure in patients with T2DM <xref rid="dom12572-bib-0044" ref-type="ref">44</xref>. The effects of empagliflozin on CV and microvascular outcomes are being investigated in the EMPA&#x02010;REG OUTCOME&#x000ae; trial (NCT01131676) <xref rid="dom12572-bib-0045" ref-type="ref">45</xref>, which will report results in the second half of 2015.</p></sec><sec id="dom12572-sec-0021"><title>Conflict of Interest</title><p id="dom12572-para-0038">R. C. has received consulting fees from Pfizer, Bristol Myers Squibb, Merck Sharp and Dohme, Takeda, Boston Scientific and Boehringer Ingelheim. I. T. has received consulting fees/payments for lectures and support for travel to meetings from Boehringer Ingelheim. C. C. has received grants from Accumetrics, Arisaph, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck and Takeda, and consulting fees from Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Essentialis, GlaxoSmithKline, Kowa, Merck, Takeda, Lipimedix, Pfizer, Regeneron and Sanofi. S. C., H. J. W., U. C. B. and O. E. J. are employees of Boehringer Ingelheim.</p><p id="dom12572-para-0039">O. E. J. planned the study. U. C. B. and O. E. J. contributed to the study design and interpretation of data and writing of the manuscript. R. C., I. T., and C. P. C. contributed to the acquisition and interpretation of data and reviewed/edited the manuscript. S. C. and H. J. W. contributed to the interpretation of data and reviewed/edited the manuscript. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12572-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Changes in blood pressure and heart rate in cohorts 1 and 2.</p></caption><media xlink:href="DOM-17-1180-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12572-supitem-0002"><caption><p>
<bold>Table S1.</bold> Patient demographics and baseline characteristics.</p></caption><media xlink:href="DOM-17-1180-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12572-sec-0020"><title>Acknowledgements</title><p id="dom12572-para-0037">The studies that provided data for these analyses were funded by Boehringer Ingelheim and Eli Lilly and Company. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Clare Ryles and Wendy Morris of Fleishman&#x02010;Hillard Group Ltd during the preparation of this manuscript.</p></ack><ref-list content-type="cited-references" id="dom12572-bibl-0001"><title>References</title><ref id="dom12572-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12572-cit-0001">
<collab collab-type="authors" id="dom12572-gp-0001">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes&#x02010;2015</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>(Suppl. 1): <fpage>S1</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="dom12572-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12572-cit-0002">
<collab collab-type="authors" id="dom12572-gp-0002">Emerging Risk Factors Collaboration</collab>
, <string-name>
<surname>Sarwar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Seshasai</surname>
<given-names>SR</given-names>
</string-name> et&#x02009;al. <article-title>Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta&#x02010;analysis of 102 prospective studies</article-title>. <source>Lancet</source>
<year>2010</year>; <volume>375</volume>: <fpage>2215</fpage>&#x02013;<lpage>2222</lpage>.<pub-id pub-id-type="pmid">20609967</pub-id></mixed-citation></ref><ref id="dom12572-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12572-cit-0003">
<collab collab-type="authors" id="dom12572-gp-0003">[ESC/EASD] Task Force on Diabetes, Pre&#x02010;diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD)</collab>
, <string-name>
<surname>Ryd&#x000e9;n</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name> et&#x02009;al. <article-title>ESC guidelines on diabetes, pre&#x02010;diabetes, and cardiovascular diseases developed in collaboration with the EASD&#x02013;summary</article-title>. <source>Diab Vasc Dis Res</source>
<year>2014</year>; <volume>11</volume>: <fpage>133</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">24800783</pub-id></mixed-citation></ref><ref id="dom12572-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12572-cit-0004">
<string-name>
<surname>Creager</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>L&#x000fc;scher</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Cosentino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Beckman</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I</article-title>. <source>Circulation</source>
<year>2003</year>; <volume>108</volume>: <fpage>1527</fpage>&#x02013;<lpage>1532</lpage>.<pub-id pub-id-type="pmid">14504252</pub-id></mixed-citation></ref><ref id="dom12572-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12572-cit-0005">
<string-name>
<surname>Hsueh</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Wyne</surname>
<given-names>K</given-names>
</string-name>. <article-title>Renin&#x02010;angiotensin&#x02010;aldosterone system in diabetes and hypertension</article-title>. <source>J Clin Hypertens (Greenwich)</source>
<year>2011</year>; <volume>13</volume>: <fpage>224</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">21466617</pub-id></mixed-citation></ref><ref id="dom12572-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12572-cit-0006">
<string-name>
<surname>Wei</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>. <article-title>Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress</article-title>. <source>BMC Cardiovasc Disord</source>
<year>2013</year>; <volume>13</volume>: <fpage>13</fpage>.<pub-id pub-id-type="pmid">23497312</pub-id></mixed-citation></ref><ref id="dom12572-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12572-cit-0007">
<string-name>
<surname>Lastra</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Syed</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kurukulasuriya</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Manrique</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sowers</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Type 2 diabetes mellitus and hypertension: an update</article-title>. <source>Endocrinol Metab Clin North Am</source>
<year>2014</year>; <volume>43</volume>: <fpage>103</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">24582094</pub-id></mixed-citation></ref><ref id="dom12572-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12572-cit-0008">
<string-name>
<surname>Stehouwer</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>I</given-names>
</string-name>. <article-title>Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease</article-title>. <source>Diabetologia</source>
<year>2008</year>; <volume>51</volume>: <fpage>527</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">18239908</pub-id></mixed-citation></ref><ref id="dom12572-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12572-cit-0009">
<string-name>
<surname>Wagenseil</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Mecham</surname>
<given-names>RP</given-names>
</string-name>. <article-title>Elastin in large artery stiffness and hypertension</article-title>. <source>J Cardiovasc Transl Res</source>
<year>2012</year>; <volume>5</volume>: <fpage>264</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">22290157</pub-id></mixed-citation></ref><ref id="dom12572-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12572-cit-0010">
<string-name>
<surname>Vlachopoulos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aznaouridis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stefanadis</surname>
<given-names>C</given-names>
</string-name>. <article-title>Prediction of cardiovascular events and all&#x02010;cause mortality with arterial stiffness: a systematic review and meta&#x02010;analysis</article-title>. <source>J Am Coll Cardiol</source>
<year>2010</year>; <volume>55</volume>: <fpage>1318</fpage>&#x02013;<lpage>1327</lpage>.<pub-id pub-id-type="pmid">20338492</pub-id></mixed-citation></ref><ref id="dom12572-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12572-cit-0011">
<string-name>
<surname>Nilsson</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Boutouyrie</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cunha</surname>
<given-names>P</given-names>
</string-name> et&#x02009;al. <article-title>Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention</article-title>. <source>J Hypertens</source>
<year>2013</year>; <volume>31</volume>: <fpage>1517</fpage>&#x02013;<lpage>1526</lpage>.<pub-id pub-id-type="pmid">23743805</pub-id></mixed-citation></ref><ref id="dom12572-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12572-cit-0012">
<string-name>
<surname>Chow</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rabkin</surname>
<given-names>SW</given-names>
</string-name>. <article-title>The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systematic meta&#x02010;analysis</article-title>. <source>Heart Fail Rev</source>
<year>2015</year>; <volume>20</volume>: <fpage>291</fpage>&#x02013;<lpage>303</lpage>.<pub-id pub-id-type="pmid">25716909</pub-id></mixed-citation></ref><ref id="dom12572-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12572-cit-0013">
<string-name>
<surname>Jung</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>KJ</given-names>
</string-name> et&#x02009;al. <article-title>Differential associations of central and brachial blood pressure with carotid atherosclerosis and microvascular complications in patients with type 2 diabetes</article-title>. <source>BMC Cardiovasc Disord</source>
<year>2014</year>; <volume>14</volume>: <fpage>23</fpage>.<pub-id pub-id-type="pmid">24555866</pub-id></mixed-citation></ref><ref id="dom12572-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12572-cit-0014">
<string-name>
<surname>Nilsson</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Cederholm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eeg&#x02010;Olofsson</surname>
<given-names>K</given-names>
</string-name> et&#x02009;al. <article-title>Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR)</article-title>. <source>Diabetes Metab</source>
<year>2009</year>; <volume>35</volume>: <fpage>439</fpage>&#x02013;<lpage>446</lpage>.<pub-id pub-id-type="pmid">19819740</pub-id></mixed-citation></ref><ref id="dom12572-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12572-cit-0015">
<string-name>
<surname>Yu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Simmons</surname>
<given-names>D</given-names>
</string-name>. <article-title>Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with type 2 diabetes: a population&#x02010;based case&#x02010;control study</article-title>. <source>Diabet Med</source>
<year>2015</year>; <volume>32</volume>: <fpage>1201</fpage>&#x02013;<lpage>1206</lpage>.<pub-id pub-id-type="pmid">25594137</pub-id></mixed-citation></ref><ref id="dom12572-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12572-cit-0016">
<string-name>
<surname>Kodama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Horikawa</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fujihara</surname>
<given-names>K</given-names>
</string-name> et&#x02009;al. <article-title>Meta&#x02010;analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus</article-title>. <source>Am J Cardiol</source>
<year>2014</year>; <volume>113</volume>: <fpage>1058</fpage>&#x02013;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">24462067</pub-id></mixed-citation></ref><ref id="dom12572-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12572-cit-0017">
<string-name>
<surname>Vlachopoulos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aznaouridis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>O'Rourke</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Safar</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Baou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stefanadis</surname>
<given-names>C</given-names>
</string-name>. <article-title>Prediction of cardiovascular events and all&#x02010;cause mortality with central haemodynamics: a systematic review and meta&#x02010;analysis</article-title>. <source>Eur Heart J</source>
<year>2010</year>; <volume>31</volume>: <fpage>1865</fpage>&#x02013;<lpage>1871</lpage>.<pub-id pub-id-type="pmid">20197424</pub-id></mixed-citation></ref><ref id="dom12572-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12572-cit-0018">
<string-name>
<surname>Dolan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Thijs</surname>
<given-names>L</given-names>
</string-name> et&#x02009;al. <article-title>Ambulatory arterial stiffness index: rationale and methodology</article-title>. <source>Blood Press Monit</source>
<year>2006</year>; <volume>11</volume>: <fpage>103</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">16534413</pub-id></mixed-citation></ref><ref id="dom12572-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12572-cit-0019">
<string-name>
<surname>Kollias</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stergiou</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Dolan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>E</given-names>
</string-name>. <article-title>Ambulatory arterial stiffness index: a systematic review and meta&#x02010;analysis</article-title>. <source>Atherosclerosis</source>
<year>2012</year>; <volume>224</volume>: <fpage>291</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">22632918</pub-id></mixed-citation></ref><ref id="dom12572-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12572-cit-0020">
<string-name>
<surname>White</surname>
<given-names>WB</given-names>
</string-name>. <article-title>Heart rate and the rate&#x02010;pressure product as determinants of cardiovascular risk in patients with hypertension</article-title>. <source>Am J Hypertens</source>
<year>1999</year>; <volume>12</volume>: <fpage>50S</fpage>&#x02013;<lpage>55S</lpage>.<pub-id pub-id-type="pmid">10090295</pub-id></mixed-citation></ref><ref id="dom12572-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12572-cit-0021">
<string-name>
<surname>Inoue</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ohkubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kikuya</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study</article-title>. <source>Am J Hypertens</source>
<year>2012</year>; <volume>25</volume>: <fpage>568</fpage>&#x02013;<lpage>575</lpage>.<pub-id pub-id-type="pmid">22318510</pub-id></mixed-citation></ref><ref id="dom12572-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12572-cit-0022">
<string-name>
<surname>Grempler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin, a novel selective sodium glucose cotransporter&#x02010;2 (SGLT&#x02010;2) inhibitor: characterisation and comparison with other SGLT&#x02010;2 inhibitors</article-title>. <source>Diabetes Obes Metab</source>
<year>2012</year>; <volume>14</volume>: <fpage>83</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21985634</pub-id></mixed-citation></ref><ref id="dom12572-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12572-cit-0023">
<string-name>
<surname>Roden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eilbracht</surname>
<given-names>J</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double&#x02010;blind, placebo&#x02010;controlled, phase 3 trial</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2013</year>; <volume>1</volume>: <fpage>208</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">24622369</pub-id></mixed-citation></ref><ref id="dom12572-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12572-cit-0024">
<string-name>
<surname>H&#x000e4;ring</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Merker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seewaldt&#x02010;Becker</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin as add&#x02010;on to metformin in patients with type 2 diabetes: a 24&#x02010;week, randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>1650</fpage>&#x02013;<lpage>1659</lpage>.<pub-id pub-id-type="pmid">24722494</pub-id></mixed-citation></ref><ref id="dom12572-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12572-cit-0025">
<string-name>
<surname>H&#x000e4;ring</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Merker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seewaldt&#x02010;Becker</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin as add&#x02010;on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24&#x02010;week, randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>3396</fpage>&#x02013;<lpage>3404</lpage>.<pub-id pub-id-type="pmid">23963895</pub-id></mixed-citation></ref><ref id="dom12572-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12572-cit-0026">
<string-name>
<surname>Kovacs</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Seshiah</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Swallow</surname>
<given-names>R</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin improves glycaemic and weight control as add&#x02010;on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24&#x02010;week, randomized, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Obes Metab</source>
<year>2014</year>; <volume>16</volume>: <fpage>147</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">23906415</pub-id></mixed-citation></ref><ref id="dom12572-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12572-cit-0027">
<string-name>
<surname>Tikkanen</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Narko</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zeller</surname>
<given-names>C</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>420</fpage>&#x02013;<lpage>428</lpage>.<pub-id pub-id-type="pmid">25271206</pub-id></mixed-citation></ref><ref id="dom12572-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12572-cit-0028">
<string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Koiwai</surname>
<given-names>K</given-names>
</string-name> et&#x02009;al. <article-title>Effect of empagliflozin monotherapy on postprandial glucose and 24&#x02010;hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double&#x02010;blind, placebo&#x02010;controlled, 4&#x02010;week study</article-title>. <source>Cardiovasc Diabetol</source>
<year>2015</year>; <volume>14</volume>: <fpage>11</fpage>.<pub-id pub-id-type="pmid">25633683</pub-id></mixed-citation></ref><ref id="dom12572-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12572-cit-0029">
<string-name>
<surname>Cherney</surname>
<given-names>DZ</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Soleymanlou</surname>
<given-names>N</given-names>
</string-name> et&#x02009;al. <article-title>The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus</article-title>. <source>Cardiovasc Diabetol</source>
<year>2014</year>; <volume>13</volume>: <fpage>28</fpage>.<pub-id pub-id-type="pmid">24475922</pub-id></mixed-citation></ref><ref id="dom12572-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom12572-cit-0030">
<string-name>
<surname>Franklin</surname>
<given-names>SS</given-names>
</string-name>. <article-title>Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease</article-title>. <source>J Hypertens Suppl</source>
<year>1999</year>; <volume>17</volume>: <fpage>S29</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="dom12572-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom12572-cit-0031">
<string-name>
<surname>Younis</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hollander</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mayoux</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Effect of prophylactic treatment with empagliflozin on cardiac function and diabetes in CRDH rats</article-title>. <source>Diabetes</source>
<year>2014</year>; <volume>63</volume>(Suppl. 1): <fpage>A273</fpage> [1056&#x02010;P].</mixed-citation></ref><ref id="dom12572-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom12572-cit-0032">
<string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heusser</surname>
<given-names>K</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin (EMPA) has no discernable effect on muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes (T2DM) despite reductions in blood pressure (BP) and weight</article-title>. <source>Diabetes</source>
<year>2014</year>; <volume>63</volume>: <fpage>A265</fpage> (Suppl. 1).</mixed-citation></ref><ref id="dom12572-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom12572-cit-0033">
<string-name>
<surname>Baker</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Smyth</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Riche</surname>
<given-names>DM</given-names>
</string-name> et&#x02009;al. <article-title>Effects of sodium&#x02010;glucose co&#x02010;transporter 2 inhibitors on blood pressure: a systematic review and meta&#x02010;analysis</article-title>. <source>J Am Soc Hypertens</source>
<year>2014</year>; <volume>8</volume>: <fpage>262</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">24602971</pub-id></mixed-citation></ref><ref id="dom12572-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom12572-cit-0034">
<string-name>
<surname>Dengo</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Dennis</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Orr</surname>
<given-names>JS</given-names>
</string-name> et&#x02009;al. <article-title>Arterial destiffening with weight loss in overweight and obese middle&#x02010;aged and older adults</article-title>. <source>Hypertension</source>
<year>2010</year>; <volume>55</volume>: <fpage>855</fpage>&#x02013;<lpage>861</lpage>.<pub-id pub-id-type="pmid">20212267</pub-id></mixed-citation></ref><ref id="dom12572-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom12572-cit-0035">
<string-name>
<surname>Ferreira</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Leite</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Cardoso</surname>
<given-names>CRL</given-names>
</string-name>, <string-name>
<surname>Salles</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio de Janeiro type 2 diabetes cohort study</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>897</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">25678104</pub-id></mixed-citation></ref><ref id="dom12572-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dom12572-cit-0036">
<string-name>
<surname>Mullan</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Fee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>McCance</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes</article-title>. <source>Hypertension</source>
<year>2002</year>; <volume>40</volume>: <fpage>804</fpage>&#x02013;<lpage>809</lpage>.<pub-id pub-id-type="pmid">12468561</pub-id></mixed-citation></ref><ref id="dom12572-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dom12572-cit-0037">
<string-name>
<surname>Oelze</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kr&#x000f6;ller&#x02010;Sch&#x000f6;n</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Welschof</surname>
<given-names>P</given-names>
</string-name> et&#x02009;al. <article-title>The sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor empagliflozin improves diabetes&#x02010;induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e112394</fpage>.<pub-id pub-id-type="pmid">25402275</pub-id></mixed-citation></ref><ref id="dom12572-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dom12572-cit-0038">
<string-name>
<surname>Lin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Koibuchi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>Y</given-names>
</string-name> et&#x02009;al. <article-title>Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice</article-title>. <source>Cardiovasc Diabetol</source>
<year>2014</year>; <volume>13</volume>: <fpage>148</fpage>.<pub-id pub-id-type="pmid">25344694</pub-id></mixed-citation></ref><ref id="dom12572-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="dom12572-cit-0039">
<collab collab-type="authors" id="dom12572-gp-0004">AstraZeneca Pharmaceuticals LLP</collab>
. <article-title>Farxiga&#x02122; (dapagliflozin) US prescribing information</article-title>. <year>2014</year>.</mixed-citation></ref><ref id="dom12572-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="dom12572-cit-0040">
<collab collab-type="authors" id="dom12572-gp-0005">Boehringer Ingelheim Pharmaceuticals, Inc.</collab>
<article-title>Jardiance<sup>&#x000ae;</sup> (empagliflozin) US prescribing information</article-title>. <year>2014</year>.</mixed-citation></ref><ref id="dom12572-bib-0041"><label>41</label><mixed-citation publication-type="miscellaneous" id="dom12572-cit-0041">
<collab collab-type="authors" id="dom12572-gp-0006">Janssen Pharmaceticals Inc.</collab>
<article-title>Invokana&#x02122; (canagliflozin) US prescribing information</article-title>. <year>2014</year>.</mixed-citation></ref><ref id="dom12572-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dom12572-cit-0042">
<string-name>
<surname>Frishman</surname>
<given-names>WH</given-names>
</string-name>. <article-title>Increased vascular compliance/decreased cardiovascular risk: what the studies tell us</article-title>. <source>Heart Dis</source>
<year>2000</year>; <volume>2</volume>: <fpage>384</fpage>&#x02013;<lpage>388</lpage>.<pub-id pub-id-type="pmid">11728287</pub-id></mixed-citation></ref><ref id="dom12572-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dom12572-cit-0043">
<string-name>
<surname>Cameron</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Asmar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Struijker&#x02010;Boudier</surname>
<given-names>H</given-names>
</string-name> et&#x02009;al. <article-title>Current and future initiatives for vascular health management in clinical practice</article-title>. <source>Vasc Health Risk Manag</source>
<year>2013</year>; <volume>9</volume>: <fpage>255</fpage>&#x02013;<lpage>264</lpage>.<pub-id pub-id-type="pmid">23745049</pub-id></mixed-citation></ref><ref id="dom12572-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="dom12572-cit-0044">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wanner</surname>
<given-names>C</given-names>
</string-name> et&#x02009;al. <article-title>SGLT&#x02010;2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials</article-title>. <source>Diab Vasc Dis Res</source>
<year>2015</year>; <volume>12</volume>: <fpage>90</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">25589482</pub-id></mixed-citation></ref><ref id="dom12572-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="dom12572-cit-0045">
<string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Lachin</surname>
<given-names>JM</given-names>
</string-name> et&#x02009;al. <article-title>Rationale, design, and baseline characteristics of a randomized, placebo&#x02010;controlled cardiovascular outcome trial of empagliflozin (EMPA&#x02010;REG OUTCOME&#x02122;)</article-title>. <source>Cardiovasc Diabetol</source>
<year>2014</year>; <volume>13</volume>: <fpage>102</fpage>.<pub-id pub-id-type="pmid">24943000</pub-id></mixed-citation></ref></ref-list></back></article>